Antibodies and processes for preparing the same
View Patent ↗Provided herein are various processes for the improved production of antibody producing organisms, antibody producing tissues, antibody producing cells and antibodies. In certain embodiments, provided herein are methods for rapidly producing antibody producing organisms, tissues, cells and antibodies derived from humans, organisms, plants or cells that are genetically altered to over-express certain proteins.
1. A fusion peptide, comprising:
(a) a protein transduction domain sequence, wherein the protein transduction domain sequence is an HIV Tat protein transduction domain sequence or a viral protein R (vpr) protein transduction domain sequence;
(b) a full-length MYC sequence having a biological activity of MYC; and
(c) at least two protein tags, wherein the protein tags comprise a 6-histidine tag and a V5 epitope tag;
wherein the fusion peptide is able to enter the nucleus of a cell.
2. The fusion peptide of claim 1 , wherein the protein transduction domain sequence is an HIV Tat protein transduction domain sequence.
3. The fusion peptide of claim 2 , wherein the Tat protein transduction domain sequence is selected from the group consisting of TAT [48-57] ; and TAT[ 57-48] .
4. The fusion peptide of claim 2 , wherein the Tat protein transduction domain sequence is SEQ ID NO:6.
5. The fusion peptide of claim 1 , wherein the protein transduction domain sequence is a Viral Protein R (vpr) protein transduction domain sequence.
6. The fusion peptide of claim 1 , wherein the MYC sequence is SEQ ID NO:1.
7. The fusion peptide of claim 1 , wherein the fusion peptide comprises SEQ ID NO:5.
8. The fusion peptide of claim 1 , wherein the fusion peptide has the following sequence:
MRKKRRQRRRMDFFRVVENQQPPATMPLNVSFTNRNYDLDYDSVQPYFYC
DEEENFYQQQQQSELQPPAPSEDIWKKFELLPTPPLSPSRRSGLCSPSYV
AVTPFSLRGDNDGGGGSFSTADQLEMVTELLGGDMVNQSFICDPDDETFI
KNIIIQDCMWSGFSAAAKLVSEKLASYQAARKDSGSPNPARGHSVCSTSS
LYLQDLSAAASECIDPSVVFPYPLNDSSSPKSCASQDSSAFSPSSDSLLS
STESSPQGSPEPLVLHEETPPTTSSDSEEEQEDEEEIDVVSVEKRQAPGK
RSESGSPSAGGHSKPPHSPLVLKRCHVSTHQHNYAAPPSTRKDYPAAKRV
KLDSVRVLRQISNNRKCTSPRSSDTEENVKRRTHNVLERQRRNELKRSFF
ALRDQIPELENNEKAPKVVILKKATAYILSVQAEEQKLISEEDLLRKRRE
QLKHKLEQLRKGELNSKLEGKPIPNPLLGLDSTRTGHHHHHH
(SEQ ID NO: 5).
9. The fusion protein of claim 1 , wherein the MYC activity comprises regulating transcriptional activity of Myc responsive genes.
10. The fusion protein of claim 1 , wherein the MYC activity comprises antibody production.
11. The fusion protein of claim 1 , wherein the MYC activity comprises cell proliferation.
12. A composition comprising:
(a) a fusion peptide, comprising:
(i) a protein transduction domain sequence, wherein the protein transduction domain sequence is an HIV Tat protein transduction domain sequence or a viral protein R (vpr) protein transduction domain sequence;
(ii) a full-length MYC sequence having a biological activity of MYC; and
(iii) at least two protein tags, wherein the protein tags comprise a 6-histidine tag and a V5 epitope tag:
wherein the fusion peptide is able to enter the nucleus of a cell; and
(b) one or more pharmaceutically acceptable excipients.
13. The composition of claim 12 , wherein the protein transduction domain sequence is an HIV Tat protein transduction domain sequence.
14. The composition of claim 13 , wherein the Tat protein transduction domain sequence is selected from the group consisting of TAT [45-57] and TAT[ 57-48] .
15. The composition of claim 13 , wherein the Tat protein transduction domain sequence is SEQ ID NO:6.
16. The composition of claim 12 , wherein the protein transduction domain sequence is a vpr protein transduction domain sequence.
17. The composition of claim 12 , wherein the MYC sequence is SEQ ID NO:1.
18. The composition of claim 12 , wherein the fusion peptide comprises SEQ ID NO:5.
19. The composition of claim 12 , wherein the fusion peptide has the following sequence:
MRKKRRQRRRMDFFRVVENQQPPATMPLNVSFTNRNYDLDYDSVQPYFYC
DEEENFYQQQQQSELQPPAPSEDIWKKFELLPTPPLSPSRRSGLCSPSYV
AVTPFSLRGDNDGGGGSFSTADQLEMVTELLGGDMVNQSFICDPDDETFI
KNIIIQDCMWSGFSAAAKLVSEKLASYQAARKDSGSPNPARGHSVCSTSS
LYLQDLSAAASECIDPSVVFPYPLNDSSSPKSCASQDSSAFSPSSDSLLS
STESSPQGSPEPLVLHEETPPTTSSDSEEEQEDEEEIDVVSVEKRQAPGK
RSESGSPSAGGHSKPPHSPLVLKRCHVSTHQHNYAAPPSTRKDYPAAKRV
KLDSVRVLRQISNNRKCTSPRSSDTEENVKRRTHNVLERQRRNELKRSFF
ALRDQIPELENNEKAPKVVILKKATAYILSVQAEEQKLISEEDLLRKRRE
QLKHKLEQLRKGELNSKLEGKPIPNPLLGLDSTRTGHHHHHH
(SEQ ID NO: 5).
20. The composition of claim 12 , wherein the MYC activity comprises regulating transcriptional activity of Myc responsive genes.
21. The composition of claim 12 , wherein the MYC activity comprises antibody production.
22. The composition of claim 12 , wherein the MYC activity comprises cell proliferation.